Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition

Treatment patterns of advanced malignant melanoma (stage III–IV) – A review of current standards in Europe

(2016) Mark Harries et al.   EUROPEAN JOURNAL OF CANCER

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

(2016) Aude G. Chapuis et al.   JOURNAL OF EXPERIMENTAL MEDICINE

RLIP76-dependent suppression of PI3K/AKT/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer

(2015) Jing Yang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes

(2015) Ana Herrero et al.   CANCER CELL

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma

(2015) Paola Queirolo et al.   CANCER TREATMENT REVIEWS

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

(2015) M. A. Wilson et al.   CLINICAL CANCER RESEARCH

KRAS as a Therapeutic Target

(2015) F. McCormick   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

(2015) A. D. Cox et al.   CLINICAL CANCER RESEARCH

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma

(2015) Juliet Richman et al.   EXPERT OPINION ON PHARMACOTHERAPY

New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma

(2015) Matteo S. Carlino et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

(2015) Christian Posch et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas

(2015) Jinhua Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors

(2015) S. R. Whittaker et al.   MOLECULAR CANCER THERAPEUTICS

Cancer: The Ras renaissance

(2015) Heidi Ledford   NATURE

Regulation of RAF protein kinases in ERK signalling

(2015) Hugo Lavoie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

(2015) Daniele Perna et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic Advances and Treatment Options in Metastatic Melanoma

(2015) Douglas B. Johnson et al.   JAMA Oncology

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

(2015) Melanie Sweetlove et al.   Frontiers in Oncology

The Renaissance of Ras

(2014) Lech-Gustav Milroy et al.   ACS Chemical Biology

A Review of Novel Therapies for Melanoma

(2014) Chante Karimkhani et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

The MAPK pathway across different malignancies: A new perspective

(2014) Mauricio Burotto et al.   CANCER

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response

(2014) Elda Grabocka et al.   CANCER CELL

KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport

(2014) Malte Schmick et al.   CELL

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

(2014) T. Smyth et al.   MOLECULAR CANCER THERAPEUTICS

Small RNA combination therapy for lung cancer

(2014) W. Xue et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway

(2014) Alexander Gross et al.   Targeted Oncology

Development of siRNA Payloads to Target KRAS-Mutant Cancer

(2014) T. L. Yuan et al.   Cancer Discovery

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

(2013) Matthew J Sale et al.   BRITISH JOURNAL OF PHARMACOLOGY

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis

(2013) Rubeta N. Matin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

(2013) Gunther Zimmermann et al.   NATURE

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

(2013) Jessie Villanueva et al.   Cell Reports

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) R. Dummer et al.   ANNALS OF ONCOLOGY

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

(2012) Zhao Chen et al.   NATURE

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis

(2012) Hao-Hsuan Jeng et al.   Nature Communications

Elucidating Distinct Roles for NF1 in Melanomagenesis

(2012) Ophélia Maertens et al.   Cancer Discovery

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

A Mouse Model of Melanoma Driven by Oncogenic KRAS

(2010) C. Milagre et al.   CANCER RESEARCH

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

(2010) Jonas N Søndergaard et al.   Journal of Translational Medicine

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE